Similar articles for PMID: 22891170

Year	Number of Results
2003	1
2005	1
2006	1
2007	1
2008	5
2009	3
2010	13
2011	16
2012	10
2013	13
2014	10
2015	5
2016	5
2019	1
2024	0

1

Five-year optical coherence tomography follow-up of an everolimus-eluting bioresorbable vascular scaffold: changing the paradigm of coronary stenting?

Karanasos A, Simsek C, Serruys P, Ligthart J, Witberg K, van Geuns RJ, Sianos G, Zijlstra F, Regar E. Karanasos A, et al. Circulation. 2012 Aug 14;126(7):e89-91. doi: 10.1161/CIRCULATIONAHA.112.110122. Circulation. 2012. PMID: 22891170 No abstract available.

2

Optical coherence tomography imaging of everolimus-eluting bioresorbable vascular scaffold implanted into coronary vein graft at 3-month follow-up.

Roleder T, Parma Z, Smolka G, Ochała A, Wojakowski W. Roleder T, et al. Eur Heart J. 2014 Sep 1;35(33):2207. doi: 10.1093/eurheartj/ehu140. Epub 2014 Apr 10. Eur Heart J. 2014. PMID: 24722807 No abstract available.

3

Three-year results of clinical follow-up after a bioresorbable everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB trial.

Onuma Y, Serruys PW, Ormiston JA, Regar E, Webster M, Thuesen L, Dudek D, Veldhof S, Rapoza R. Onuma Y, et al. EuroIntervention. 2010 Sep;6(4):447-53. doi: 10.4244/EIJ30V6I4A76. EuroIntervention. 2010. PMID: 20884431 Clinical Trial.

4

ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: rationale and study design.

Diletti R, Serruys PW, Farooq V, Sudhir K, Dorange C, Miquel-Hebert K, Veldhof S, Rapoza R, Onuma Y, Garcia-Garcia HM, Chevalier B. Diletti R, et al. Am Heart J. 2012 Nov;164(5):654-63. doi: 10.1016/j.ahj.2012.08.010. Am Heart J. 2012. PMID: 23137495 Clinical Trial.

5

Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes.

Serruys PW, Onuma Y, Dudek D, Smits PC, Koolen J, Chevalier B, de Bruyne B, Thuesen L, McClean D, van Geuns RJ, Windecker S, Whitbourn R, Meredith I, Dorange C, Veldhof S, Hebert KM, Sudhir K, Garcia-Garcia HM, Ormiston JA. Serruys PW, et al. J Am Coll Cardiol. 2011 Oct 4;58(15):1578-88. doi: 10.1016/j.jacc.2011.05.050. J Am Coll Cardiol. 2011. PMID: 21958884 Free article. Clinical Trial.

6

Five-year follow-up of the ABSORB bioresorbable everolimus-eluting vascular scaffold system: multimodality imaging assessment.

García-García HM, Schultz C, Duckers E, Regar E, Ligthart J, Serruys PW, van Geuns RJ. García-García HM, et al. EuroIntervention. 2013 Feb 22;8(10):1126-7. doi: 10.4244/EIJV8I10A187. EuroIntervention. 2013. PMID: 23014900 Free article. No abstract available.

7

First-in-human description of everolimus-eluting bioabsorbable vascular scaffold implantation for the treatment of drug-eluting stent failure: insights from optical coherence tomography.

Grasso C, Attizzani GF, Patané M, Ohno Y, Capodanno D, Tamburino C. Grasso C, et al. Int J Cardiol. 2013 Oct;168(4):4490-1. doi: 10.1016/j.ijcard.2013.06.127. Epub 2013 Jul 24. Int J Cardiol. 2013. PMID: 23890924 No abstract available.

8

Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients with two treated vessels: 2-year results from the SPIRIT III randomised trial.

Applegate RJ, Hermiller JJ, Sanz M, Doostzadeh J, Pierson W, Su X, Lansky AJ, Sudhir K, Stone GW. Applegate RJ, et al. EuroIntervention. 2010 Sep;6(4):437-46. doi: 10.4244/EIJ30V6I4A75. EuroIntervention. 2010. PMID: 20884430 Clinical Trial.

9

[Vessel response evaluation by optical coherence tomography after drug-eluting stent implantation in the left main coronary artery].

Giuliani G, Maehara A, Parodi G. Giuliani G, et al. G Ital Cardiol (Rome). 2010 Mar;11(3):246. G Ital Cardiol (Rome). 2010. PMID: 20550066 Italian. No abstract available.

10

ComparisOn of neointimal coVerage betwEen zotaRolimus-eluting stent and everolimus-eluting stent using Optical Coherence Tomography (COVER OCT).

Kim JS, Kim BK, Jang IK, Shin DH, Ko YG, Choi D, Hong MK, Cho YK, Nam CW, Hur SH, Choi JH, Song YB, Hahn JY, Choi SH, Gwon HC, Jang Y. Kim JS, et al. Am Heart J. 2012 Apr;163(4):601-7. doi: 10.1016/j.ahj.2011.10.016. Am Heart J. 2012. PMID: 22520526 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

78 results

Results by year